Direct answer for buyers
No. We do not offer Retatrutide, Semaglutide, Tirzepatide or other GLP-1 receptor agonists as cosmetic microneedle patch OEM or private-label products. These names relate to pharmaceutical development or prescription-drug pathways, not ordinary cosmetic peptide ingredients.
Why a GLP-1 microneedle patch is not a cosmetic product
Product category follows intended use, active ingredient, claims and delivery mechanism. A patch intended to deliver a drug for weight management, blood-glucose control or another therapeutic purpose cannot be converted into a cosmetic simply by using beauty packaging or the words “research use only.” A drug-loaded microneedle system may also raise combination-product and device questions.
Status of the commonly searched ingredients
| Search term | Regulatory context | Our cosmetic OEM position |
|---|---|---|
| Retatrutide microneedle patch | Investigational drug-related ingredient; not an FDA-approved cosmetic active or an approved drug at publication. | Not offered. |
| Semaglutide microneedle patch | Semaglutide is used in FDA-approved prescription drugs for specific indications and dosage forms; that does not authorize a cosmetic patch. | Not offered. |
| Tirzepatide microneedle patch | Tirzepatide is used in FDA-approved prescription drugs for specific indications and dosage forms; that does not authorize a cosmetic patch. | Not offered. |
| GLP-1 peptide patch | A broad search phrase that may imply systemic drug delivery and therapeutic claims. | Requires a qualified pharmaceutical and regulatory pathway, outside our cosmetic OEM service. |
What we can develop instead
For skincare brands seeking peptide-led cosmetic positioning, we can assess Copper Tripeptide-1 (GHK-Cu), Acetyl Hexapeptide-8, palmitoylated cosmetic peptides and multi-peptide cosmetic systems, subject to formula compatibility, evidence and destination-market review.
Questions buyers should ask before requesting a peptide patch
- Is the proposed active a cosmetic ingredient, a drug substance or an investigational compound?
- Do the intended claims concern appearance and conditioning, or treatment and physiological change?
- Does the target market treat the microneedle geometry or delivery mechanism as a device or combination product?
- What safety, stability, content and packaging evidence is required for the final formulation?
Frequently asked questions
Can you make a Retatrutide microneedle patch for private label?
No. Retatrutide is not offered under our cosmetic OEM or private-label program.
Can Semaglutide or Tirzepatide be used in a cosmetic microneedle patch?
No. These are pharmaceutical active ingredients associated with prescription-drug pathways, not ordinary cosmetic peptide ingredients. An approved injectable drug does not authorize a cosmetic microneedle patch dosage form.
Does a research-use-only label make a GLP-1 patch acceptable for consumer sale?
No. A label disclaimer does not override the product's actual ingredients, intended use, claims, instructions or sales context.
Which peptide microneedle patches can a cosmetic brand discuss with you?
We can review cosmetic-oriented concepts such as GHK-Cu, Acetyl Hexapeptide-8, selected palmitoylated peptides and multi-peptide systems, subject to technical feasibility and destination-market assessment.
Official regulatory references
- FDA concerns with unapproved GLP-1 drugs
- FDA information on microneedling devices
- FDA combination-product definitions and examples
Explore Cosmetic Peptide Patch Options
How the Changzhou portfolio describes the GLP-1 concept
The supplied portfolio lists a peptide body-shaping concept with a 500-needle HA array, nominal height of 300–1,000 µm and a catalogue wear-time reference of 3–6 hours. Its formulation line says “GLP-1-related active ingredients” without identifying a substance, dose or exposure. This is a research reference, not a validated medicine, a Retatrutide specification or a consumer treatment offer.